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Inhibition of host-encoded targets, such as the
cyclophilins, provides an opportunity to generate
potent high barrier to resistance antivirals for the
treatment of a broad range of viral diseases. How-
ever, many host-targeted agents are natural prod-
ucts, which can be difficult to optimize using
synthetic chemistry alone. We describe the orthog-
onal combination of bioengineering and semisyn-
thetic chemistry to optimize the drug-like properties
of sanglifehrin A, a known cyclophilin inhibitor of
mixed nonribosomal peptide/polyketide origin, to
generate the drug candidate NVP018 (formerly
BC556). NVP018 is a potent inhibitor of hepatitis B
virus, hepatitis C virus (HCV), and HIV-1 replication,
shows minimal inhibition of major drug transporters,
and has a high barrier to generation of both HCV and
HIV-1 resistance.
INTRODUCTION
Treatment of chronic viral diseases by direct inhibition of viral
targets frequently leads to rapid development of virally encoded
resistance. Therapies targeted to host proteins involved in the
viral life cycle offer an opportunity to both raise the barrier to
generation of resistance and generate antivirals able to treat a
broad range of viral diseases. However, this has been hindered
in the past by the relative rarity of targets essential to the virus
but nonessential to the host, and the inherent complexity of
discovering and developing drugs that effectively target these
proteins.
From the 1940s to 2007, 73% of the 155 small molecules
approved as anticancer drugs were of natural origin, either
directly or derived (Newman and Cragg, 2007). As opposed to
this, few natural products (NPs) had been approved for use inChemistry & Biology 22, 285antiviral therapy, although they were the inspiration for antiviral
nucleoside analogs (Chung and Cutler, 1992).
Many bacterial NPs, including the well-described polyketide
class, have been shown to bind to and inhibit mammalian cellular
proteins, including viral host-encoded targets such as cyclophi-
lins, v-ATPases (Hunt et al., 2011), CRM1 (Scheifele et al., 2002),
and Hsp90 (Momose et al., 2002). They can be produced at low
cost of goods by fermentation, and frequently the lead com-
pound has both excellent potency against the target and good
cellular penetration. However, NPs often display polypharmacol-
ogy and have less than optimal mammalian pharmacokinetics
and physicochemical properties.
The tools available for optimizing NPs are ever increasing.
Specifically, bioengineering has been proposed as a way
to reinvigorate NP drug discovery (Hutchinson, 1994; Wilkinson
and Micklefield, 2007). In the past, semisynthetic approaches
have been the most frequently used route to improve the
drug-like properties of an NP hit. However, the available
semisynthetic options are predetermined by the array of
functional groups on the NP. In contrast, bioengineering
options are predetermined by the biosynthetic pathway. The
potential changes are thus orthogonal to those available to
semisynthesis.
Whole-genome sequencing is now straightforward and easily
affordable, and for NP classes such as the modular polyketide
synthases (PKSs), knowledge of the DNA sequence encoding
the biosynthetic gene cluster enables rapid understanding of
gene product function. When combined with improved tech-
niques for DNA transfer and the rapid targeted alteration of
biosynthetic genes, this provides a powerful platform for
focused drug discovery efforts with the aim of improving
drug-like properties and pharmacokinetics and reducing off-
target effects. These bioengineering techniques are readily
combined with semisynthesis to identify molecules with further
improved properties. In particular, inactivation of precursor
pathways can allow mutasynthesis, the process of feeding a
synthetic analog of the precursor which is then incorporated,
biosynthetically, into the final molecule (Gregory et al., 2005;–292, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 285
Figure 1. Overview of Biosynthetic Medici-
nal Chemistry Route to Generate BC544
and NVP018.Kennedy, 2008). This enables a combinatorial element in
bioengineering.
Cyclophilins are a class of peptidyl-prolyl isomerases, proteins
that catalyze the cis-trans isomerization of the peptide bond pre-
ceding prolyl residues. Knockout studies in several species,
including mice and human cells, confirm that they have limited
or no effect on cellular growth and survival (Luvisetto et al.,
2008; Elrod et al., 2010; Dolinski et al., 1997; Colgan et al.,
2000). However, cyclophilins recruited from host cells have
been shown to have essential roles in many viral life cycles.
Initially, cyclophilin A was shown to be incorporated into HIV-1
virions (Thali et al., 1994; Franke et al., 1994) involved in viral
replication, its expression level in patients being related to the
speed of progression to AIDS (An et al., 2007). Isomerase activity
of cyclophilin A, and potentially others such as cyclophilin B and
cyclophilin 40, have been shown to be required for hepatitis C
virus (HCV) replication (Chatterji et al., 2009; Yang et al., 2008;
Kaul et al., 2009). Other viruses in which cyclophilin involvement
has been implicated in their life cycle or cyclophilin inhibitors
have shown inhibitory activity include vaccinia virus (Damaso
and Moussatche´, 1998), West Nile virus, Dengue virus, yellow
fever virus (Qing et al., 2009), hepatitis B virus (HBV) (Ptak
et al., 2008), human papilloma virus (Bienkowska-Haba et al.,
2009), cytomegalovirus (CMV) (Kawasaki et al., 2007), SARS
coronavirus (Pfefferle et al., 2011), Japanese encephalitis virus
(Kambara et al., 2011), and influenza A (Liu et al., 2012).
We now describe the use of combined bioengineering and
semisynthetic approaches to optimize the drug-like properties
of sanglifehrin A, an NP cyclophilin inhibitor, to generate
NVP018 (formerly BC556). Preclinical analysis reveals NVP018
to be a molecule displaying in vitro inhibition of HBV and HCV
and potent in vitro and oral in vivo inhibition of HIV-1.286 Chemistry & Biology 22, 285–292, February 19, 2015 ª2015 Elsevier Ltd All rights reservRESULTS
Bioengineering and Mutasynthesis
of Streptomyces sp. A92-308110
Previous semisynthetic derivatization to
replace the spirolactam fragment of
sanglifehrin A led to generation of the san-
gamides, molecules with improved solu-
bility, potency, and selectivity (Moss
et al., 2012). This approach moved the
immunosuppressive NPs from tool com-
pounds appropriate for chemical ge-
netics to being compounds that could
reasonably be pursued as therapeutic
agents. We then used bioengineering to
make further alterations to the macrocy-
clic portion of the molecule, changes
that could not have otherwise been
done without complex total synthesis.
The major aim of this work was to further
improve the drug-like properties of thefinal molecule by specific manipulation of the parts of the mole-
cule involved in cyclophilin binding.
The gene cluster required for biosynthesis of sanglifehrin A has
been published (Qu et al., 2010). Generation of the sanglifehrins
requires 13 typical PKS extension modules and three nonriboso-
mal peptide synthetase (NRPS) modules incorporating L-valine,
meta-L-tyrosine, and L-piperazic acid. In addition, a crotonyl-
CoA reductase/carboxylase (CCR) is present for generation of
the PKS starter unit (2E)-2-ethylmalonyl-CoA, an iterative type I
PKS is required for the supply of the unique (2S)-2-(2-oxo-
butyl)malonyl-CoA extender unit, and a phenylalanine hydroxy-
lase produces the NRPS extender unit meta-L-tyrosine from
L-phenylalanine.
Analysis of the published crystal structures of sanglifehrin A
(Kallen et al., 2005) and an analog with the spirolactam fragment
removed (Sedrani et al., 2003) suggested that manipulation of
the electronics on the meta-L-tyrosine moiety might lead to
improved binding to cyclophilins. To achieve this, we inactivated
sfaA, the gene encoding the phenylalanine hydroxylase respon-
sible for meta-L-tyrosine biosynthesis. Deletion of sfaA was car-
ried out by homologous recombination, following conjugation of
a plasmid containing the appropriate deletion construct into
Streptomyces sp. A92-308110 using standard techniques
(Kieser et al., 1999), and led to the strain BIOT-4585. Due to
the lack of meta-L-tyrosine production, BIOT-4585 did not pro-
duce sanglifehrin A unless fed withmeta-L-tyrosine or an analog.
Synthesis and Selection of NVP018
A screen was then carried out by feeding a selection of appro-
priate meta-L-tyrosine analogs to BIOT-4585 to determine its
ability to generate sanglifehrin analogs (see Figure 1). Fermenta-
tions with those analogs successfully accepted as substratesed
Table 1. Comparison of Cyclophilin Inhibition, HCV NS5A-
Cyclophilin A Complex Disruption, and Genotype 1b Replicon
Inhibition for Cyclosporin and Sanglifehrin Analogs
CypA
PPIase
IC50 (nM)
NS5A-CypA
disruption
IC50 (mM)
HCV Huh5.2
Gt1b replicon
EC50 (nM)
HCV Gt1b
replicon
CC50 (mM)
CsA 9.7 ± 1.30 0.98 ± 0.08 306 ± 141 4.4
Alisporivir 0.8 ± 0.05 0.24 ± 0.02 96 ± 23 11.2
BC544 2.7 ± 0.2 0.36 ± 0.03 125 ± 22 >100
NVP018 0.3 ± 0.03 0.10 ± 0.01 33 ± 10 >100were scaled up to allow isolation of new sanglifehrins. The anti-
viral activity and ADME (absorption, distribution, metabolism,
excretion) properties of each analog were analyzed, and the
best of the analogs were subjected to semisynthesis to yield
the corresponding sangamides as described previously (Moss
et al., 2012). The resulting sangamides were again analyzed for
antiviral activity and ADME properties, and from this NVP018
was chosen as a potential drug candidate (data not shown).
NVP018 is derived from a sanglifehrin resulting from incorpora-
tion of 5-fluoro-meta-L-tyrosine. Semisynthesis replaced the spi-
rolactam-containing portion of the sanglifehrin with a tertiary
hydroxamic amide moiety (Table S1). Of the sangamides tested,
NVP018 had the best combination of properties (Table 1),
including more potent inhibition of CypA PPIase activity and in-
hibition of HCV replicons.
NVP018 Has Reduced Off-Target Inhibition of Drug
Transporters
One of the issues with cyclosporin-based cyclophilin inhibitors
is off-target inhibition of transporter proteins. Alisporivir, for
example, inhibits multiple transporter proteins, including
OATP1B1, OATP1B3, and MRP2, which are involved in bilirubin
transport. It is this inhibition which is now thought to be the
mechanism for the dose-limiting hyperbilirubinemia (Avila et al.,
2012). These compounds also have drug-drug interaction con-
cerns through inhibition of xenobiotic transporters such as Pgp
and BSEP (Kapturczak and Kaplan, 2004; Wring et al., 2010).
Comparison of the inhibition of these transporters using vesicu-
lar transport or uptake transporter inhibition assays, and in vitro
inhibition of the xenobiotic transporters Pgp and BSEP revealed
that while alisporivir (ALV) and cyclosporin A (CsA) potently in-
hibited many of them, BC544 (Figure 1, previously stated as
compound 3o in Moss et al., 2012) and NVP018 showedminimal
or no inhibition (see Table 2). To test the effect of NVP018 on bili-
rubin levels, we then dosed three mice with up to 250 mg/kg/day
NVP018 for 7 days. In all cases, almost no increase was seen in
either bilirubin or liver enzymes when measured at the end of the
study (see Table S2).
NVP018 Displays In Vivo Pharmacokinetics Suitable for
Once-Daily Dosing
To confirm bioavailability following oral dosing, a single oral dose
of 5 mg/kg was given to groups of mice, rats, and dogs. In all
cases, blood concentrations were maintained above the HCV
EC90 for 24–48 hr post dose (Figure 2). Liver levels were found
to be 3- to 6-fold higher than blood levels, and up to 230-foldChemistry & Biology 22, 285higher than plasma levels, revealing further concentration within
the target organ for treatment of hepatic disease (see Table S3).
Analysis of other organs in rats, including brain, heart, and lungs,
revealed much lower exposure following oral dosing compared
with the blood and liver, probably because of first-pass extrac-
tion by the liver.
NVP018 Is an Inhibitor of HCV Replication In Vitro
Until recently the standard-of-care treatment for chronic HCV
infection has been a combination of interferon and ribavirin for
6–12 months. Use of recently approved drugs with high barrier
to resistance, such as the nucleotide polymerase inhibitor (NPI)
sofosbuvir, leads to high levels of viral clearance (AASLD 2011,
abstract; Sulkowski et al., 2012). Cyclophilin inhibition is one of
the few mechanisms of action of HCV inhibition that consistently
shows a high barrier to resistance, and in phase 2 trials some pa-
tients were clear of the virus after being treated for 24 weeks with
1000 mg/day ALV monotherapy (Pawlotsky et al., 2012). Alispor-
ivir, a nonimmunosuppressive semisynthetic derivative of CsA,
is a potent cyclophilin inhibitor which was in phase 3 trials for
the treatment of HCV infection. NVP018 could provide a suitable
alternative backbone for use in an interferon-free combination.
Comparison of the inhibitory potential of NVP018 with the semi-
synthetic sangamide, BC544, and ALV against HCV replicons re-
vealed that NVP018wasmuchmore potent in all assays, andwas
similarly active against all genotypes tested (see Table 3). Analysis
of the effect of increasing levels of either human serumor fetal calf
serum (FCS) also confirmed that there was no effect on antiviral
potency with addition of up to 40% serum (see Table S4).
To compare the barrier to resistance of NVP018 in HCV, Huh7-
Con1 cells were serially passaged for 7 weeks in the presence of
300 mg/ml G418 and increasing concentrations of NVP018 or
ALV. Colonies were amplified, and cellular RNA extracted and
analyzed by quantitative RT-PCR. For all ALV-resistant repli-
cons, only the previously described and clinically relevant
D320E mutation was consistently found in all clones analyzed.
In the case of NVP018-resistant replicons, all clones analyzed
contained the same five mutations: L27I, R318W, D320E,
S370P, and C446S. When NVP018 was tested against separate
replicons containing individual mutations from this list, only the
D320E mutation was shown to confer more than 2-fold resis-
tance alone. The combination of all five mutations only led to
4-fold resistance compared with the wild-type.
NVP018 Is an Inhibitor of HBV Replication In Vitro
There have been previous reports that cyclophilin inhibitors such
as CsA have an inhibitory effect on HBV replication (Xia et al.,
2005). We therefore tested NVP018 in two in vitro models to
look for inhibitory activity. The first involved transfecting Huh7
cells with HBV DNA (8 mg) in the presence of 2 mM NVP018,
ALV, or DMSO. After days 0, 1, 2, and 3, amounts of de novo
HBV proteins HBsAg and HBeAg present in cell extracts or su-
pernatants were quantified by ELISA, in triplicate. Data shown
in Table 3 revealed that NVP018 and ALV potently inhibited
HBV replication at this concentration. An additional assay was
run using HepG2 cells stably expressing replicating HBV. These
were treated with DMSO, NVP018, or ALV at three concentra-
tions (0.1, 1, and 10 mM). The effect onHBV replicationwasmoni-
tored by treating HepG2 cells with test article at the relevant–292, February 19, 2015 ª2015 Elsevier Ltd All rights reserved 287
Table 2. Comparison of Solubility, Plasma Protein Binding, and Transporter Inhibition
Solubility in PBS
pH 7.4 (mM)
Human plasma protein
binding (fraction
unbound) (%)
OATP1B1
IC50 (mM)
OATP1B3
IC50 (mM) MRP2 IC50 (mM) Pgp IC50 (mM) BSEP IC50 (mM)
CsA 36 <1 0.85 0.13 4.1 0.73 0.46
Alisporivir 15 <4 0.45 0.19 16 (>49%) 0.72 0.18
BC544 330 28 10.97 5.40 >50 >50 29.3
NVP018 140 22 4.31 1.75 >50 >50 12.3concentration for 3 days, removing the supernatant, retreating
and analyzing after an additional 48 and 72 hr by HBsAg ELISA,
HBeAg ELISA, and for HBVDNA, in triplicate, in both cell extracts
and supernatants. This assay confirmed a dose-dependent
effect of NVP018 against HBV replication at the final time point.
NVP018 Is an Inhibitor of HIV-1 Replication In Vitro
Although no cyclophilin inhibitors are currently in clinical devel-
opment for treatment of HIV-1 infection, ALV was originally
developed as an inhibitor of HIV-1 replication, and showed a
mean 1 log drop in viral load following 14 days of dosing in
HIV/HCV-coinfected patients (Flisiak et al., 2008). We therefore
tested NVP018 in comparison with BC544 and ALV in a CD4+
HeLa HIV-1 inhibitory fluorescence-activated cell sorting
(FACS) assay to see if improvements in inhibition of in vitro
HCV replicons carried through to HIV-1 inhibitory assays.
NVP018 was found to be more potent both as regards HIV-1
EC50 (see Table 3) and in terms of maximal viral inhibition, which
was seen to reach >95% inhibition with sanglifehrin analogs
including BC544 and NVP018 but only 60% with CsA and ALV.
These data were similar when repeated in Jurkat cells, activated
CD4+ peripheral blood T lymphocytes, and macrophages. One
of the concerns with development of ALV for the treatment of
HIV-1 was the presence of natural isolates with the H86Q ALV-
resistant genotype (Ptak et al., 2008). NVP018 was tested
against both laboratory-generated and natural H86Q isolates,
and was found to be active in both cases.
NVP018 Is a Potent Inhibitor of HIV-1 Replication In Vivo
As NVP018 had shown both potent in vitro HIV-1 inhibition and
oral bioavailability, its effect on HIV-1 viral replication in the
SCID-hu Thy/Liv mouse model was assessed. This model has
been well validated against other standard HIV therapies and is
thought to be a highly reproducible model with relevance to clin-
ical effect (Stoddart et al., 2007).
To enable comparison with data from previous studies with
approved agents in the model, NVP018 or ALV was dosed orally
bidaily for 14 days, starting 1 day before inoculation with the
NL4.3 virus, at 50 mg/kg/day or 100 mg/kg/day.
Administration of NVP018 gave >6 log10 reductions in HIV-1
RNA, and was more potent than ALV at protecting thymocytes
and in reducing HIV-1 RNA and p24 levels at all concentrations
tested (see Figure 3). No overt signs of toxicity were seen in
any of the mice at any dose level. The potency of NVP018 com-
pares well with data previously published by Stoddart et al.
(2007), as the >6 log10 HIV-1 RNA log drop seen following
NVP018 dosing was more pronounced than for approved thera-
pies such as efavirenz, atazanavir, emtricitabine, and nevirapine,288 Chemistry & Biology 22, 285–292, February 19, 2015 ª2015 Elsewhich showed 1–4 log10 viral RNA reductions after 21 days’
bidaily dosing at 100 mg/kg.
DISCUSSION
The cyclophilin inhibitor NVP018 was generated using a combi-
nation of semisynthetic and bioengineering methods. These are
frequently used independently, but in the past have been less
commonly used together (Kennedy, 2008; Eichner et al., 2012).
This enabled a combinatorial approach to NP drug discovery
and led to the selection of NVP018, a compound with more
potent cyclophilin inhibition, antiviral potency versus HBV,
HCV, and HIV-1, and reduced off-target transporter inhibition
compared with the parent compound, sanglifehrin A. A fluorine
was introduced into the compound by mutasynthesis, a method
that has been successful in introducing this substitution pattern
in a less invasive way than semisynthetic chemistry (Weist et al.,
2002; Hojati et al., 2002; Goss et al., 2010; Knobloch et al., 2012;
Almabruk et al., 2013).
Second-generation cyclophilin inhibitors, such as NVP018,
have the potential for therapeutic application in a number of
areas, in particular chronic viral infection. This is due to their po-
tency, high barrier to resistance, activity on multiple steps of the
viral life cycle, and oral bioavailability. It is also worth noting the
recent publications suggesting that these compounds might
also have additional impact on interferon regulatory factors,
which have long been implicated in the escape of certain viruses,
such as HCV and HIV, from the immune system (Obata et al.,
2005; Bobardt et al., 2013). While cyclophilin inhibitors do not
exhibit inhibition of all viruses, they have been shown to have
activity against a wide variety of both RNA viruses (e.g. corona-
viruses, HIV, and HCV) and DNA viruses (human CMV, HBV,
varicella zoster virus). It is therefore tempting to speculate that
cyclophilin inhibitors may be a step in the direction of agents
with broad antiviral activity (Katze et al., 2002).
We also anticipate that in the era of rapid genome sequencing
and gene synthesis, bioengineering applications will continue to
become more amenable and offer a more flexible route to
improve NPs with potent inhibition of cellular targets, but with
less than optimum drug-like properties. We hope that in the
future, bioengineering and semisynthesis will be used more
frequently in combination to optimize NPs with an aim to select
candidates for clinical development.
SIGNIFICANCE
Moss et al. describe the generation and preclinical analysis
of a bacterial natural product with activity as a host targetedvier Ltd All rights reserved
NVP018
Figure 2. Mean Blood Concentration-Time Profiles of NVP018
Following a Single Oral Dose of 5 mg/kg to CD-1 Mice, SD Rats, or
Beagle Dogs
Values represent the average concentrations calculated in groups of 3 mice
with standard deviation shown with error bars.antiviral drug. This was achieved by a combination of
biosynthetic engineering and semisynthetic chemistry –
bringing together the advantages of each method to more
efficiently optimize a bacterially produced, genetically en-
coded natural product. The preclinical analysis reveals
potent activity against HCV, HIV, and HBV and a significantly
improved profile compared with both the parent natural
product and the cyclosporin A (CsA) class of cyclophilin in-
hibitors, of which alisporivir was in phase 3 for treatment
of chronic HCV infection.
EXPERIMENTAL PROCEDURES
Compounds
BC544 was synthesized according to the method published by Moss et al.
(2012) (compound 3o therein). Alisporivir (DEBIO-025/DEB025) was synthe-
sized according to the method published in US6,927,208 from CsA (>99%)
purchased from LC Labs, Woburn, MA, USA.
Genetic Engineering of Streptomyces sp. A92-308110
In-frame deletion of the sfaA gene, coding for the tyrosine hydroxylase, was
carried out using double recombination. The recombinant strain generated,
BIOT-4585, could then be fed (S)-methyl 2-amino-3-(3-fluoro-5-hydroxy-
phenyl)propanoate hydrochloride salt and grown under appropriateTable 3. EC50 of Cross Genotype HCV Replicon Inhibition and IC50 o
HCV HIV-1 H
HCV Huh7
Gt1a replicon
EC50 (nM)
HCV Huh7
Gt1b replicon
EC50 (nM)
HCV Huh7
Gt2a replicon
EC50 (nM)
HIV-1 HeLa
cells IC50 (nM)
H
s
D
CsA 198 ± 13 137 ± 4 455 ± 37 5300 N
Alisporivir 98 ± 11 76 ± 5 102 ± 8 1500 ± 240 >
BC544 63 ± 4 58 ± 5 89 ± 6 310 ± 20 6
NVP018 18 ± 2 13 ± 1 21 ± 3 130 ± 15 9
HBVdata shows IC50 of HepG2 cells stably replicating HBV following treatme
(T/C) value after 3 days of Huh7 cells following transfection with HBVDNA in
Chemistry & Biology 22, 285fermentation conditions to generate BC457. Further details are available in
the Supplementary Information.
Semisynthesis of NVP018 from BC457
NVP018 was synthesized in three steps from BC457 using the same protocol
as for compound BC544. In brief, BC457 was treated via modified Sharpless
dihydroxylation conditions to form a diol, which was subsequently cleaved
to generate an allylic aldehyde by the action of sodium periodate. Finally,
the resultant allylic aldehyde was coupled with a suitable amide under
Horner-Wadsworth-Emmons coupling conditions.
ADME Compound Analysis
Solubility analysis, plasma protein binding, intravenous and oral pharmacoki-
netics, and toxicology were carried out using standard methods at Shanghai
Chempartner, Shanghai, and efflux assays were carried out at Solvo Biotech-
nology, Hungary or Cyprotex, UK. Further details are available in the Supple-
mentary Information.
ELISA Analysis of CypA-NS5A Interactions
Test articles were tested for their capacities to block the interaction between
CypA andHCVNS5A by ELISA. Specifically, we produced and purified recom-
binant glutathione S-transferase (GST), GST-CypA, and Con1 NS5A-His pro-
teins and conducted ELISA. Nunc MaxiSorb eight-well strip plates were
coated with GST or GST-CypA for 16 hr at 4C and blocked. Recombinant
NS5A-His (1 ng/ml) was added to wells in 50 ml of binding buffer (20 mM Tris
[pH 7.9], 0.5 M NaCl, 10% glycerol, 10 mM DTT, and 1% NP-40) for 16 hr at
4C. Captured NS5A-His was subsequently detected using mouse anti-His
antibodies (1 mg/ml) (anti-6xHis, Clontech) and rabbit antimouse-horseradish
peroxidase phosphatase (HRP) antibodies (1:1000 dilution). To test the effect
of test articles on the CypA-NS5A complex formation, increasing concentra-
tions of each test article were added to GST-CypA together with recombinant
NS5A. All experiments were conducted twice. Data are presented in triplicate
(inhibitory concentration of 50% [IC50]).
PPIase Inhibition Analysis
The inhibition of the PPIase activity of CypA was used to compare the inhib-
itory potential of sanglifehrin derivatives as an indication of their binding affin-
ity to CypA. The PPIase activity of recombinant CypA, produced by thrombin
cleavage of GST-CypA, is determined by following the rate of hydrolysis of
N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide by chymotrypsin. Chymotrypsin
only hydrolyzes the trans form of the peptide, and hydrolysis of the cis
form, the concentration of which is maximized by using a stock dissolved in
trifluoroethanol containing 470 mM LiCl, is limited by the rate of cis-trans
isomerization. CypA was equilibrated for 1 hr at 5C with selected sanglifehrin
derivatives using a drug concentration range from 0.1 to 20 nM. The reaction
was started by addition of the peptide, and the change in absorbance was
monitored spectrophotometrically at 10 data points per second. The blank
rates of hydrolysis (in the absence of CypA) were subtracted from the rates
in the presence of CypA. The initial rates of the enzymatic reaction were
analyzed by first-order regression analysis of the time course of the change
in absorbance. All sanglifehrin derivatives exhibited anti-PPIase activity thatf HIV-1 and HBV Inhibition
BV
BV Huh7
table HBV
NA IC50 (nM)
HBV Huh7
stable HBsAg
IC50 (nM)
HBV Huh7
stable HBeAg
IC50 (nM)
HBV HepG2
transfected HBsAg
T/C day 3 at 2 mM (%)
A NA NA NA
10,000 >10,000 >10,000 18
10 600 280 9.6
50 520 350 8.8
nt with DMSO, tenofovir, BC544, NVP018, and alisporivir, and test/control
the presence of DMSO, tenofovir, BC544, NVP018, and alisporivir at 2 mM.
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Figure 3. Comparison of Implant P24 Levels, T lymphocytes, and
HIV-1 RNA in the SCID-hu Thy/Liv Mouse Model, Following Bidaily
Doses of Either 50 or 100 mg/kg Alisporivir (ALV) or NVP018 for 2
Weeks
*p % 0.05 compared with untreated mice. Values represent the average
concentrations/numbers calculated in a group of 6 mice with standard devi-
ation shown with error bars.correlated well with their capacity to prevent CypA-NS5A interactions
analyzed by ELISA or pulldown.
HCV Antiviral Assay Huh 5-2
Anti-HCV assay in Huh 5-2 cells was performed by seeding 6.5 3 103 cells
per well in a tissue-culture-treated white 96-well view plate (Packard, Can-
berra, Canada) in Dulbecco’s modified essential medium (DMEM) supple-
mented with 250 mg/ml G418. Following incubation for 24 hr at 37C (5%
CO2), medium was removed and 3-fold serial dilutions in complete DMEM
(without G418) of the test compounds were added in a total volume of
100 ml. After 4 days of incubation at 37C, cell culture medium was removed
and luciferase activity was determined using the luciferase assay system
(Promega, Leiden, the Netherlands); the luciferase signal was measured us-
ing a Safire2 (Tecan, Switzerland). Relative luminescence units were con-290 Chemistry & Biology 22, 285–292, February 19, 2015 ª2015 Elseverted to percentage of untreated controls. The 50% effective concentration
(EC50) was defined as the concentration of compound that reduced the lucif-
erase signal by 50%.
Cytostatic Assay
For the assessment of the potential cytostatic effect of the evaluated inhibitor,
cells were seeded at a density of 6.5 3 103 cells per well of a 96-well plate in
complete DMEM. Serial dilutions of the test compounds in complete DMEM
were added 24 hr after seeding. Cells were allowed to proliferate for 3 days at
37C,afterwhich thecell numberwasdeterminedbymeansof the (3-(4,5-dime-
thylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium)/phenazinemethosulfate (MTS/PMS) method (Promega). The CC50 (value
derived from the dose-response curve) represents the concentration at which
themetabolic activity of the cellswould be reduced to 50%of themetabolic ac-
tivity of untreated cells. The selectivity index, indicating the therapeutic window
of the compound, was calculated as the CC50/EC50.
HCV Replicon Antiviral Assays
The replicon cells (subgenomic replicons of genotype 1a [H77], 1b [Huh7], and
2a [JFH-1]) were grown in DMEM, 10% fetal bovine serum (FBS), 1%penicillin-
streptomycin (pen-strep), 1% glutamine, 1% nonessential amino acids, and
250 mg/ml G418 in a 5% CO2 incubator at 37
C. All cell culture reagents
were purchased fromMediatech (Herndon, VA). The replicon cells were trypsi-
nized and seeded at 53 103 cells per well in 96-well plates with the above me-
dia without G418. On the following day, the culture medium was replaced with
DMEM containing compounds serially diluted in the presence of 5% FBS. The
cells containing the HCV replicon were seeded into 96-well plates and test ar-
ticles were serially diluted with DMEM plus 5% FBS. The diluted compound
was then applied to appropriate wells in the plate. After 72 hr of incubation
at 37C, the cells were processed. The intracellular RNA from each well was
extracted with an RNeasy 96 kit (Qiagen). The level of HCV RNA was deter-
mined by a real-time RT-PCR assay using TaqMan One-Step RT-PCR Master
Mix Reagents (Applied Biosystems, Foster City, CA) and an ABI Prism 7900
sequence detection system (Applied Biosystems). The cytotoxic effects
were measured with TaqMan Ribosomal RNA Control Reagents (Applied Bio-
systems) as an indication of cell numbers. The amount of the HCV RNA and
rRNA were then used to derive applicable EC50 values (concentration that
would inhibit the replicon replication by 50%).
In Vitro Assays for Assessment of HBV Antiviral Activity
HepG2 cells stably replicating robustly HBV were treated with DMSO, tenofo-
vir, BC544, NVP018, and ALV at three concentrations (0.1, 1, and 10 mM).
Effect on HBV replication was monitored by treating HepG2 cells with test
article at the relevant concentration for 3 days, removing the supernatant, re-
treating, and analyzing after an additional 72 hr by HBsAg ELISA, HBeAg
ELISA, and HBV DNA in triplicate in cell extracts. These data were used to
generate test/control values, which were plotted against the test article con-
centration and used to calculate IC50 values.
Huh7 cells were transfected with HBV DNA (8 mg) in the presence of DMSO,
tenofovir, BC544, NVP018, and ALV at 2 mM. After day 3, amounts of de novo
HBsAg protein present in cell extracts or supernatants were quantified by
ELISA in triplicate. This was used to calculate a test/control value.
In Vitro Assay for Assessment of HIV Antiviral Activity
Antiviral efficacy against HIV may be tested as follows. Blood-derived CD4+ T
lymphocytes and macrophages were isolated as described previously (Bo-
bardt et al., 2008). In brief, human peripheral bloodmononuclear cells (PBMCs)
were purified from fresh blood by banding on Ficoll-Hypaque (30 min, 800 g,
25C). Primary human CD4+ T cells were purified from PBMCs by positive se-
lection with anti-CD4 Dynabeads and subsequent release using Detachabead.
Cells were cultured in RPMImedium 1640 (Invitrogen) supplementedwith 10%
FCS, MEM amino acids, L-glutamine, MEM vitamins, sodium pyruvate, and
penicillin plus streptomycin, and were subsequently activated with bacterial
superantigen staphylococcal enterotoxin B (SEB; 100 ng/ml) and mitomycin
C-killed PBMCs from another donor (10:1 PBMC:CD4 cell ratio). Three days
after stimulation, cells were split 1:2 in medium containing interleukin-2 (IL-2)
(200 units/ml final concentration). Cultures were then split 1:2 every 2 days
in IL-2medium and infected with HIV at 7 days after stimulation. For generatingvier Ltd All rights reserved
primary human macrophages, monocytes were purified from human PBMCs
by negative selection and activated and cultured at a cell concentration
of 106/ml in DMEM, supplemented with 10% FCS, MEM amino acids, L-gluta-
mine, MEM vitamins, sodium pyruvate, and penicillin (100 units/ml),
streptomycin (100 mg/ml), and 50 ng/ml recombinant human granulocyte–
macrophage colony-stimulating factor (GM-CSF), and maintained at 37C in
a humidified atmosphere supplemented with 5% CO2. To obtain monocyte-
derived macrophages, cells were allowed to adhere to plastic and cultured
for 6 days to allow differentiation.
CD4+ HeLa cells, Jurkat cells, activated CD4+ peripheral blood T lympho-
cytes, and macrophages (500,000 cells/100 ml) were incubated with pNL4.3-
GFP (X4 virus) or pNL4.3-BaL-GFP (R5 virus) (100 ng of p24) in the presence
of increasing concentrations of test article; 48 hr later, infection was scored
by analyzing the percentage of GFP-positive cells by FACS and the EC50
calculated.
SCID-hu Thy/Liv Mouse Model
Stocks of NL4-3 (X4 virus) were prepared by transfection of 293T cells and
collection of supernatants on day 2. Supernatants were filtered, aliquoted,
and frozen at 80C until use. Amounts of virus were quantified by p24 ELISA
and infectivity of viral stocks verified using CD4+ HeLa-b-galactosidase re-
porter cells.
Human fetal thymus and liver were obtained from Advanced Bioscience
Resources in accordance with federal, state, and local regulations. Coimplan-
tation of thymus and liver fragments under the kidney capsule to create SCID-
hu Thy/Liv mice and inoculation of the Thy/Liv implants with HIV-1 (1000
TCID50 HIV-1 per Thy/Liv implant by direct injection) were carried out as
described (Rabin et al., 1996; Namikawa et al., 1990). Male C.B-17 SCID
(model #CB17SC-M, homozygous, C.B-Igh-1b/IcrTac-Prkdcscid) mice
were obtained at 6–8 weeks of age from Taconic, and cohorts of 50–60
SCID-hu Thy/Liv mice were implanted with tissues from a single donor.
Implants were inoculated 18 weeks after implantation with 50 ml of stock virus
or complete DMEM (control infection) by direct injection. Animal protocols
were approved by the TSRI Institutional Animal Care and Use Committee.
Groups of six mice each were treated with NVP018 or ALV at 50 or
100 mg/kg/day by twice-daily oral gavage until implant collection 2 weeks
after inoculation.
Implants were dispersed through nylon mesh into single-cell suspensions
and assessed for p24 by ELISA (p24 [ELISA]: intracellular Gag pg/106 cells),
for viral RNA (bDNA assay: copies/106 cells), and for depletion of thymocyte
subsets by flow cytometry (% of CD3, CD4, CD8) as described previously
(Stoddart et al., 2007; Rabin et al., 1996; Stoddart et al., 2000). Specifically,
implant cells were stained with phycoerythrin cyanine dye CY7-conjugated
anti-CD4 (BD Biosciences), phycoerythrin cyanine CY5.5-conjugated
anti-CD8 (Caltag), allophycocyanin cyanine CY7-conjugated anti-CD3
(eBiosciences), and phycoerythrin-conjugated anti-W6/32 (DakoCytomation).
Cells were fixed and permeabilized with 1.2% paraformaldehyde and 0.5%
Tween 20, stained with fluorescein isothiocyanate-conjugated anti-p24 (Beck-
man Coulter), and analyzed on an LSR II (BD Biosciences). After collecting
100,000 total cell events, percentages of marker-positive (CD4+, CD8+, and
CD4+CD8+) thymocytes in the implant samples were determined by first
gating on a live lymphoid cell population identified by forward- and side-
scatter characteristics and then by CD3 expression. Total RNA was extracted
from frozen thymocyte pellets using Trizol LS (Invitrogen) and resuspended in
nuclease-free water. The capsid region of the HIV-1 gag was amplified by
RT-PCR using 10 ml of purified RNA and AmpliTaq Gold (Applied Biosystems)
according to the manufacturer’s instructions.
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